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Abstract
Introduction: Compartmental modelling is an established method of quantifying
18F-FDG uptake; however, only recently has it been applied to evaluate pulmonary
inflammation. Implementation of compartmental models remains challenging in the
lung, partly due to the low signal-to-noise ratio compared to other organs and the lack
of standardisation. Good reproducibility is a key requirement of an imaging biomarker
which has yet to be demonstrated in pulmonary compartmental models of 18F-FDG; in
this paper, we address this unmet need.
Methods: Retrospective subject data were obtained from the EVOLVE observational
study: Ten COPD patients (age= 66 ± 9; 8M/2F), 10 α1ATD patients (age= 63 ± 8;
7M/3F) and 10 healthy volunteers (age= 68 ± 8; 9M/1F) never smokers. PET and CT
images were co-registered, and whole lung regions were extracted from CT using an
automated algorithm; the descending aorta was defined using a manually drawn
region. Subsequent stages of the compartmental analysis were performed by two
independent operators using (i) a MIAKATTM based pipeline and (ii) an in-house
developed pipeline. We evaluated the metabolic rate constant of 18F-FDG (Kim) and the
fractional blood volume (Vb); Bland-Altman plots were used to compare the results.
Further, we adjusted the in-house pipeline to identify the salient features in the analysis
which may help improve the standardisation of this technique in the lung.
Results: The initial agreement on a subject level was poor: Bland-Altman coefficients
of reproducibility for Kim and Vb were 0.0031 and 0.047 respectively. However, the
effect size between the groups (i.e. COPD, α1ATD and healthy subjects) was similar
using either pipeline. We identified the key drivers of this difference using an
incremental approach: ROI methodology, modelling of the IDIF and time delay
estimation. Adjustment of these factors led to improved Bland-Altman coefficients of
reproducibility of 0.0015 and 0.027 for Kim and Vb respectively.
Conclusions: Despite similar methodology, differences in implementation can lead to
disparate results in the outcome parameters. When reporting the outcomes of lung
compartmental modelling, we recommend the inclusion of the details of ROI
methodology, input function fitting and time delay estimation to improve
reproducibility.
Keywords: Positron emission tomography computed tomography, Kinetic modelling,
Lung inflammation, Fluorodeoxyglucose F18, Reproducibility of results, Pulmonary
disease, Chronic obstructive, Biomarkers
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Introduction
Inflammation is a hallmark of many respiratory diseases and is thought to be com-
plicit in the progression of chronic lung diseases such as chronic obstructive pulmonary
disease (COPD). The limitations of clinical measurements to quantify pulmonary inflam-
mation are well documented [1]. 18F-FDG PET-CT is a non-invasive imaging technique;
quantification of 18F-FDG uptake has emerged as a promising biomarker to assess
lung inflammation [2]. Recruitment of inflammatory cells requires increased glucose
utilisation; therefore, 18F-FDG uptake should be elevated in inflammatory pathologies [3].
A major challenge in quantifying 18F-FDG in the lung is the poor signal-to-noise ratio;
the low basal uptake of FDG is a consequence of the low density of lung tissue (due to
large proportions of air). Interpretation is further confounded by FDG within pulmonary
blood, which in the healthy lung is substantially larger (typically 15–20%) than other
organs, e.g. the brain (typically 5%). Static measures, such as the standard uptake value
(SUV), are likely to be heavily influenced by these factors which has led to the exploration
of alternative methods that account for these effects [4].
Kinetic modelling has traditionally been regarded as the gold standard method of quan-
tification in PET studies; well established applications include estimation of cerebral
metabolic rate (CMR) and neurological receptor binding (a general framework for kinetic
modelling is described in [5]). In the lung, kinetic modelling has recently been used to
explicitly account for the effects of air and blood on the rate of 18F-FDG uptake [6, 7]
which may lead to a better estimation of underlying inflammation. Provided there is not
significant oedema, the two compartment irreversible model [8] has been widely adopted
to model the kinetics of 18F-FDG in pulmonary inflammation [9] (see Fig. 1).
The concentration of 18F-FDG measured in a region of interest (ROI) within the lung
can be described by:
Cm(t) = VbCb(t) + (1 − Va − Vb)Ct(t,K1, k2, k3,Vb) + VaCa(t) (1)
where Cm(t) is the concentration of 18F-FDG in the ROI; Cb(t) and Ct(t) are the concen-
trations of 18F-FDG in the pulmonary blood vessels and lung cells respectively. Va and Vb
are the fractional volumes of air and blood respectively. K1, k2 and k3 are the micropa-
rameters of the model [5]. The concentration of radioactivity in air, Ca(t), is assumed
negligible. Va can be derived from a CT image as described in [10].
Fig. 1 Irreversible two compartmental model describing the kinetics of 18F-FDG used to evaluate lung
inflammation. In the absence of significant oedema, the concentration of 18F-FDG in a ROI in the lung can be
described by three compartments [9]: a blood compartment Cb(t), an extravascular pre-cursor pool Ce(t) and
phosphorylated (’trapped’) 18F-FDG compartment Cp(t). The relationships between the concentration of
tracer in a compartment is described by the rate constants (i.e. K1, k2, k3). ROI = Region of Interest
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The metabolic rate constant of 18F-FDG is then given by
Kim = K1k3/(k2 + k3) (2)
The microparameters and Vb are estimated by minimising the weighted residual sum
of squares (WRSS):
WRSS= ∑Ni=1Wi(Y (i) − Cm(i))2 (3)
where N is the number of time frames of the dynamic scan, i is the frame number and
Wi is the weighting factor for each frame, Cm(i) is the estimated concentration of 18F-
FDG fitted from the compartmental model in frame i (i.e. Eq. 1) and Y (i) is the measured
concentration from the PET scanner.
An essential requirement of this approach is an accurate blood input function (Cb(t))
[11]; although arterial blood samples taken during the PET scan are considered the gold
standard, obtaining samples from a peripheral vein is less invasive and onerous. Alterna-
tively, a blood TAC can be derived from the dynamic PET images by delineating a ROI
within a vessel in the field of view, referred to as an image-derived input function (IDIF).
Optimal positioning of the blood vessel ROI has been discussed extensively in application
to 18F-FDG tumour kinetics [12] and cardiac metabolism [13]; IDIFs derived from several
different vessels were found to be comparable to arterial samples. In pulmonary 18F-FDG
kinetics, several regions have been explored including the ascending and descending pul-
monary aorta, left and right ventricles and aorta [14, 15]. The TAC extracted from the
blood pool ROI is then modelled as a continuous curve to reduce noise: models based
on an initial linear rise followed by a sum of exponentials have been proposed in tumour
kinetics [16]. In the brain, extensive effort has been made to improve input function mod-
elling including those based on reference regions [17] and methods using carotid or other
blood vessels with one or more manual samples [18–20] with voxel-based approaches
also feasible [21]. In the lung, there remains a need for optimisation of input function
modelling.
Early studies of kinetic models of cerebral blood flow (CBF) demonstrated the impor-
tance of correcting the blood input function for time delay [22] (i.e. the time taken for
the tracer to travel between the blood sampling site and the tissue of interest). Methods
to estimate the delay between blood sample point and the tissue ROI are largely based
on these earlier observations in neurological PET [23, 24]. More recently, inaccuracies in
time delay were shown to cause significant deviations in the microparameters of a CMR
kinetic model in rodents [25]. This applies equally to pulmonary compartmental models
of 18F-FDG: incorporating a regional lung time delay has been shown to improve the fit
to the experimental data compared to no delay in acute lung injury (ALI) [26]. Further
corrections such as accounting for the partial volume effect (PVE) and spill-over in pul-
monary 18F-FDG scans may be important [15], but the impact of this approach on kinetic
parameter estimation in humans has yet to be explored.
The approach taken to model the input function and estimate the time delay are clearly
operator dependent with several different feasible methodologies. Further, estimation of
the microparameters in Eq. 2 depends on the chosen optimisation algorithm and the
applied variance model (i.e. choice of Wi) [27]—these too are not yet standarised in
pulmonary compartmental models. Experts in quantitative 18F-FDG lung imaging have
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recently highlighted the need to improve the standardisation of the analysis and assess the
reproducibility of the outcome parameters (e.g. Kim and Vb)[2, 28].
To this end, our aim was to evaluate the reproducibility of pulmonary compartmental
models—this has yet to be performed in 18F-FDG models of lung inflammation and, to
our knowledge, reproducibility of kinetic modelling outcomes in neurological PET also
has yet to be disclosed. Reproducibility will be influenced by the number of operator
dependent steps required to estimate Kim and Vb (see Fig. 2) and the inherent variability
associated with measurements of low signal. We investigate the reproducibility of the
analysis with two operators who independently analysed 30 lung scans using different
analysis pipelines. During the evaluation, we identified the key parameters in the analyses
which could be standarised to help improve reproducibility in pulmonary compartmental
modelling of 18F-FDG.
Methods
Study data
Thirty age and gender matched patients from the EVOLVE study were included in this
evaluation: ten patients with COPD (age= 66 ± 9; 8M/2F), ten patients with α1ATD
(age= 63±8; 7M/3F) and ten healthy never smokers (age= 68±8; 9M/1F). The EVOLVE
study was a cross-sectional multi-centre study to investigate vascular and pulmonary
inflammation (REC 13/EE/0165, UK CRN ID 1513); the primary outcomes of this study
are reported in [29]. Patients were clinically diagnosed with COPD stratified with fib-
rinogen ≤2.8g/L. Healthy volunteers (HV) were recruited if they had no regular smoking
history and normal predicted spirometry (further protocol details are available [30]).
Imaging protocol
A single bolus of approximately 240MBq 18F-FDG was injected into the antecubital vein
and images were acquired for 60 min under list mode acquisition (further details are
available in the Additional file 1). A low dose attenuation correction CT (CTAC) was
acquired under free breathing prior to PET scanning. Three subjects (1 COPD, 2 HV)
Fig. 2 Overview of the main stages of compartmental modelling used in 18F-FDG in diffuse lung disease. DA
= Descending Aorta,WL =Whole Lung, TAC = Time Activity Curve, IDIF = Image Derived Input Function
Vass et al. EJNMMI Physics            (2019) 6:26 Page 5 of 14
were removed from subsequent analysis after failing initial quality control procedures (see
Additional file 1). The blood input function was calculated using an IDIF (as described
in the following section); discrete venous blood samples were obtained as a means to
calculate a plasma-over-blood (POB) ratio.
Imaging analyses
For the initial analysis, subject data were analysed by operator A (as described in [7]) using
a Molecular Imaging and Kinetic Analysis Toolbox (MIAKATTM [31]; Version no: 4.2.6)
based pipeline—herein referred to as pipeline A. Operator B independently analysed the
same dataset using an in-house developed pipeline using MATLAB [32]—herein referred
to as pipeline B.
The pipelines shared common procedures for pre-processing: the segmentation of the
whole lung and blood vessels were performed using ITK-SNAP (www.itksnap.org [33]),
and blood TACs were obtained from an ROI manually delineated within the descending
aorta (DA), drawn in the centre of the vessel to minimise the partial volume effect. Our
rationale for using the DA is based on previous work which revealed it to be preferable
in estimating kinetic rate constants [15] and based on its previous use [7]. The principle
differences between the pipelines are outlined in Table 1.
In pipeline A, subsequent analysis was performed using a MIAKAT-based pipeline:
MIAKAT software was modified for lung 18F-FDG kinetics by operator A. Importantly,
both pipelines used the same compartmental model as the basis to estimate the metabolic
rate of 18F-FDG (Kim) and the fraction blood volume (Vb)–the main outcome parameters
for this study.
In order to understand the drivers of any differences in the results, operator B inves-
tigated the salient parts of the analysis methodology, which led to the differences and
adjusted elements of pipeline B (described in the Further investigation section) to improve
agreement.
Table 1 Comparison of two analysis pipelines used to estimate metabolic rate of 18F-FDG to assess
pulmonary inflammation
Parameter Pipeline A Pipeline B: initial Pipeline B: final
Blood ROI size Circular, 5 pixel diameter, aortic
arch to variable
Circular, 8 pixel diameter,
25 slices beginning aortic
arch
As pipeline A
Lung ROI closing and ero-
sion operation
5 pixel diameter disc 3 pixel diameter disc As pipeline B initial
Input function model Exponential basis functions Tri- or biexponential fits As pipeline A
Time delay estimation Inside compartmental model
optimisation
Outside compartmental
model optimisation
As pipeline A
Time delay fitting Delays spanning −50 to 50 s
using 1-compartmental model
fitted for first 5 min—lowest
residual sum of squares
Additional parameter
within estimation of rate
constants
As pipeline A
Optimisation Local optimum Global optimum As pipeline A
Start point of optimisation K1 = 0.5, k2 = 0.2, k3 = 0.3, Vb =
0.1
Multiple start points gen-
erated finds best guess
(lowest objective function
value)
As pipeline A
The columns “Pipeline B: initial” and “Pipeline B: final” describes the parameters which were used in the initial evaluation and the
final settings used following adjustments to pipeline B respectively. The table highlights the key differences between the
implementations of the compartmental model. Parameters not included below were identical between the analysis pipelines.WL
= whole lung, DA = descending aorta, ROI = region of interest
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Statistics
Bland-Altman plots were used to compare the different outcome variables; medians,
inter-quartile ranges and correlations were also used. The Bland-Altman coefficient of
reproducibility is given by 2× SD; we expect 95% of the difference to be less than
this value. The differences in Kim and Vb between the two pipelines were plotted as a
histogram to ensure that a normal distribution was observed. To investigate group dif-
ferences the Hedge’s g effect was used, as a further complementary measure we used
the unpaired t test. Unless otherwise stated, significance is considered when P < 0.05.
The intra-observer repeatability was assessed using the coefficient of variation (COV) by
operator B using pipeline B.
Results
Initial results are shown in Fig. 3a; boxplots show the differences in Kim between COPD,
α1ATD and controls using the two pipelines. Although a systemic offset was observed
between the values obtained between the pipelines, this did not alter the overall group-
level conclusions: the Hedge’s g factor for the difference between COPD and HV was
−0.89 for pipeline A and−0.57 for pipeline B. Further, for pipelines A and B, no significant
difference was found between these groups using the two sample t test (p = 0.088 and p =
0.26, respectively). The variance in pipeline B was greater than pipeline A in the α1ATD
Fig. 3 Boxplot of group differences in Kim between the two analysis pipelines. (a) Initial comparison between
Kim between the two analysis pipelines. (b) Comparison between Kim between the two pipelines after all
adjustments to Pipeline B (see section Further investigation).COPD = Chronic Obstructive Pulmonary Disease,
A1ATD = α 1-antitrypsin deficiency patients, HV = Healthy Volunteer, _A = Pipeline A result, _B = Pipeline B result
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group (IQR = 0.0031 vs 0.0018, respectively). There was poor agreement in Kim on a sub-
ject level between the pipelines: Fig. 4a shows the Bland-Altman plot for Kim. The mean
difference in Kim between the two platforms was 0.0041 ml · cm−3 · min−1 with upper
and lower limits of agreement (uloa and lloa) of 0.00097 and 0.0072 ml · cm−3 · min−1
respectively; the correlation coefficient was 0.62. Figure 4a indicates a systematic rela-
tionship may exist between the difference and the mean values of Kim estimated using
the two pipelines. Following the approach suggested in [34] to reduce systematic bias,
we log transformed the data, giving a mean Kim of 1.8, lloa of 1.19 and uloa of 2.73
(after transformation back to the original scale). Although the transformation improved
Fig. 4 Bland-Altman plots comparing outcome parameters of a pulmonary compartmental model of
18F-FDG. (a) Kim -the metabolic rate constant of FDG. (b)Vb -the fractional blood volume. These are the initial
results using two different analysis pipelines. Adjustment of pipeline B led to improved agreement between
the pipelines (see Fig. 6))
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the situation, the agreement between pipelines is still poor. Figure 4b shows the Bland-
Altman plot for Vb. The mean difference in Vb was −0.0015 (uloa = 0.045, lloa =
−0.048); the correlation coefficient was 0.80. The Bland-Altman coefficients of repro-
ducibility were 0.0031 and 0.047 for Kim and Vb respectively. To assess the repeatability of
analysis, ten subjects (from COPD group) were analysed five times with pipeline B (oper-
ator B): the within subject SD of Kim was 8.28 × 10−4ml · cm−3 · min−1 and the COV
was 6.1%.
Further investigation
Subsequently, we sought to understand the drivers of the difference described above;
this section describes the steps we undertook. Firstly, visual inspection of the lung tissue
TACs from pipeline A and B revealed minimal differences. Further, the mean square error
(MSE) between lung TACs from pipeline A and pipeline B was 0.11±0.040; therefore, we
concluded that the lung TACs were not responsible for the differences.
Next, we undertook a visual inspection of the blood TACs, this revealed slight differ-
ences due to the ROI methodology (e.g. size and location) used by the two operators. To
improve agreement, we applied the same DA ROImethodology: in pipeline B, we reduced
the area of each ROI and ensured the same begin and end locations in the axial slice as
pipeline A. This led to an improvement in the visual comparison of the blood TACs and
a modest improvement in Kim (mean difference between was 0.0037ml · cm−3 · min−1
compared to the original value of 0.0041 ml · cm−3 · min−1). The modelling of the blood
TAC was then compared: we found the fitting of the input functions differed chiefly in
the early stage of the scan (< 5 min post-injection)—likely due to the inherent noise due
to short frame durations. In pipeline B, we altered the input function modelling to match
the approach adopted in pipeline A. Firstly, we applied the same fitting function: here, the
blood TAC is modelled by basis functions [35] with a varying number of exponentials; the
exponential model that best fits the blood TACwas found using a least squares algorithm.
With both pipelines using this approach, the Bland-Altman coefficients of reproducibility
were modestly improved (0.0023 for Kim and 0.034 for Vb).
The time delay estimation is also highly dependent on the initial time frames of the
input function; we found an association between the difference in outcome parameters,
particularly Vb, and the estimated time delay. The mean difference in time delay estima-
tion between pipeline A and B was 3 ± 5.3 s. To improve the agreement between the
estimated time delays for each subject, we replicated in pipeline B the method outlined in
[7] (used in pipeline A). Namely, a one compartmental model was fitted to the first 5 min
of the smoothed blood TAC and lung TAC. Then, a delay of ±50 s in 1s increments was
introduced and the delay was estimated by finding the minimum value of the residual sum
of squares on the model fit. The mean difference in time delay estimation was improved
to 0.76 ± 1 s. This improved the Bland-Altman coefficient markedly to 0.016 for Kim and
0.028 for Vb.
Various factors were adjusted in the optimisation algorithm including the function,
number of iterations, tolerance and initial parameter. But these were found to have less
influence on outcome parameters. Figure 5 summarises the incremental improvement
in agreement during each stage of the evaluation as we altered pipeline B. Follow-
ing all adjustments to pipeline B, the Bland-Altman plots are shown in Fig. 6; the
mean differences were Kim = 9.0 × 10−4 ml · cm−3 · min−1 and Vb = −0.0014 with
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Fig. 5 Cumulative Bland-Altman coefficients of reproducibility for Kim during the evaluation of pipeline A
and B. Pipeline B was altered at each stage to improve the agreement in Kim , each value represents the
cumulative effect of all preceding stages. ROI = region of interest
coefficients of reproducibility of 0.0015 and 0.027. The correlation was also improved:
for Kim, r = 0.86 and for Vb, r = 0.94. Figure 3b demonstrates the improve-
ment in agreement on a group level. Kim calculated using the adjusted pipeline B
had larger variability than pipeline A in the healthy control group (IQR = 0.0031
vs 0.0022, respectively); we did not observe any notable change in the other groups
(see Fig. 3).
Discussion
We investigated the reproducibility of pulmonary compartmental modelling of inflam-
mation using two independent analysis pipelines; Kim and Vb were the main outcome
parameters of this study, Kim was interpreted as a surrogate for lung inflammation. Two
independent operators used reconstructed dynamic PET and CT scans from the same 30
subjects. Initial results showed that the subject-level agreement in Kim and Vb was poor;
despite the application of the same kinetic model (i.e. Eqs. 1 and 2). Interestingly, this
did not change the overall interpretation of the group findings; the effect size between
groups was comparable using either pipeline. Further, it did not change the outcome
of statistical hypothesis testing between groups. Reproducibility of analysis is an impor-
tant pre-requisite for an imaging biomarker; the results of this evaluation demonstrate
the need for standardisation when applying compartmental modelling to assess lung
inflammation.
The excellent repeatability of pipeline B (COV = 6.1%) indicates that the poor
agreement between the pipelines is likely to be due to the implementation of the com-
partmental model. To investigate the salient stages responsible for the differences, we
used an incremental approach: beginning with the steps involved in generating the TACs
and all subsequent stages to estimate Kim and Vb. Visual comparison of the blood input
functions revealed that the largest differences seemed to be in the stages of extracting
and modelling the blood input functions. We determined that the salient factors were
the blood ROI methodology, input function modelling and time delay estimation. ROI
definition led to differences in estimates of concentration due to presence of the PVE -
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Fig. 6 Bland-Altman plots comparing outcome parameters of a pulmonary compartmental model of
18F-FDG using two independent analysis pipelines following adjustment of pipeline B. (a) Kim -the metabolic
rate constant of FDG. (b)Vb -the fractional blood volume. This should be compared to the initial results in Fig 4
neither pipeline applied corrections for PVE; it has been suggested this could also help
reduce bias in the kinetic parameters estimation [9], but this has yet to be confirmed in
human studies. Although adjusting the ROI size did improve the agreement between the
pipelines modestly, agreement was improved substantially by the subsequent modelling
of the input function.
Modelling the input function provides a means to minimise the noise and spillover
problems in PETmeasurements [36, 37]. Variousmodels exist, common examples include
the Feng model [36] and tri-exponential equations, which use regression to estimate the
best fit to the blood TAC. In these data, we found the fitting was particularly sensitive
to the first few time frames—corresponding to the images with the largest noise content.
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There are several proposed methods to calculate the time delay between the blood input
function and the tissue of interest. We found large differences in estimates of time delay
between pipelines A and B, given its sensitivity to the first few minutes of data collection
this is clearly exacerbated if the input functionmodels produce different fits in this region.
By adjusting the blood ROI definitions, the input function fitting method and the time
delay calculation in pipeline B, we were able to demonstrate better agreement between
the two pipelines (see Figs. 3b and 6). Such parameters are often not reported in the
“Methods” section of existing literature; these findings highlight the need for reporting
details of analysis methodology to facilitate the reproducibility of outcomes in compart-
mental models of the lung. Adjustment of pipeline B led to higher variability in Kim in the
HV group. It seems likely that this is due to the higher noise content in HV scans, which
may have led to more extreme differences in fitting of the IDIF. Future work is needed to
determine the importance of this variance in pulmonary compartmental models.
The POB ratio was calculated for each subject using discrete venous blood samples;
this allows the conversion of a blood input function to a plasma input function. Although
the same factors were used for both pipelines, we recognise that this may cause bias in
the outcome variables. We found the POB ratio to be very close to one (1.05 ± 0.03);
this agrees with previous findings that 18F-FDG equilibrates between erythrocytes and
plasma nearly instantaneously [38]. Further work should determine whether POB correc-
tions are necessary in quantitative 18F-FDG lung studies. Previous work has demonstrated
that the weighting factors chosen to describe the variance of dynamic PET data affects
the outcomes of compartmental modelling [27]; here, the weighting factors were identi-
cal in both pipelines and we did not explore the impact of different weighting schemes
but acknowledge this could be another key contributor which may improve reproducibil-
ity. Respiratory motion leads to both density variations in the lung and inaccuracies in the
attenuation correction applied to the PET image; both of these influence quantitative PET
and improvements have been suggested by use of an averaged CT scan when available [4].
Since we acquired the CT scans during free breathing, these inaccuracies may have an
influence on our quantitative PET data. This study investigated the reproducibility of pul-
monary compartmental models of dynamic 18F-FDG PET/CT; since both operators used
the same reconstructed datasets, this does not include within subject biological variabil-
ity or technical factors (e.g. scanner settings and reconstruction algorithms), which would
allow the overall reproducibility of pulmonary 18F-FDG scans to be evaluated. Never-
theless, with each operator using identical scans, we avoid the systematic variability in
18F-FDG uptake introduced by differences between hardware, reconstruction and acqui-
sition protocols [39]. We were able to assess the intra-observer agreement for pipeline B
(operator B); we found this to have excellent repeatability. We could not explore the inter-
observer effect as results from pipeline A, undertaken by operator A, were retrospectively
acquired. Yet, we were able determine which stages of compartmental modelling were
responsible for the low concordance observed between the pipelines.
Currently, there is no standard method of assessing pulmonary inflammation using
compartmental models of 18F-FDG and each centre may undertake such analyses using
their own bespoke approach. Our findings suggest that despite seemingly similar method-
ology, individual subject results are sensitive to several factors in the analysis; therefore,
care is needed when reporting the exact methods used. In our lung data, we identified that
the blood ROI methodology, IDIF modelling and time delay estimation were important
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drivers of reproducibility. In light of these findings, we suggest that any forthcoming
recommendations for reporting methodology incorporate these key features.
Conclusions
Reproducibility of pulmonary compartmental modelling of 18F-FDG PET-CT was eval-
uated in 30 subjects consisting of three groups: COPD patients, α1ATD patients and
healthy never smokers. Two operators analysed the imaging data using independent
software to estimate the metabolic rate constant of 18F-FDG and fractional blood vol-
ume. Initial comparisons showed good agreement in the overall conclusions at group
level; however, subject-level agreement was poor. We identified salient factors in the
analysis, which improved the agreement between the two analysis pipelines: blood ROI
methodology, input function modelling and time delay estimation. In a field where in-
house analyses are commonplace, these findings highlight the need for standardisation in
reporting of methods, which will help to improve the reproducibility.
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